GT200600130A - Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia - Google Patents
Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofreniaInfo
- Publication number
- GT200600130A GT200600130A GT200600130A GT200600130A GT200600130A GT 200600130 A GT200600130 A GT 200600130A GT 200600130 A GT200600130 A GT 200600130A GT 200600130 A GT200600130 A GT 200600130A GT 200600130 A GT200600130 A GT 200600130A
- Authority
- GT
- Guatemala
- Prior art keywords
- treatment
- tetrahydropiridoazepin
- chichophrenia
- onas
- related compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
ESTA INVENCIÓN SE REFIERE A LOS COMPUESTOS DE FÓRMULA (1) EN LA QUE G, D, A, Q, Y, Z Y R1 A R10 SON GRUPOS FUNCIONALES DETALLADOS EN LA DESCRIPCIÓN. SE PROPORCIONAN PROCEDIMIENTOS E INTERMEDIARIOS UTILIZADOS PARA SU PREPARACIÓN, COMPOSICIONES FARMACÉUTICAS QUE CONTIENEN DICHOS COPUESTOS Y USO EN EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, ENTRE OTROS. T2006
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US66744705P | 2005-04-01 | 2005-04-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GT200600130A true GT200600130A (es) | 2007-02-14 |
Family
ID=36763625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GT200600130A GT200600130A (es) | 2005-04-01 | 2006-03-31 | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20060234997A1 (es) |
| EP (1) | EP1869041A1 (es) |
| JP (1) | JP4109709B1 (es) |
| KR (1) | KR20070112228A (es) |
| CN (1) | CN101189237A (es) |
| AP (1) | AP2007004160A0 (es) |
| AR (1) | AR053835A1 (es) |
| AU (1) | AU2006228426A1 (es) |
| BR (1) | BRPI0607918A2 (es) |
| CA (1) | CA2603049A1 (es) |
| CR (1) | CR9407A (es) |
| DO (1) | DOP2006000071A (es) |
| EA (1) | EA200701856A1 (es) |
| GT (1) | GT200600130A (es) |
| IL (1) | IL185770A0 (es) |
| MA (1) | MA29989B1 (es) |
| MX (1) | MX2007012083A (es) |
| NL (2) | NL1031489C2 (es) |
| NO (1) | NO20075477L (es) |
| PE (1) | PE20061196A1 (es) |
| TN (1) | TNSN07366A1 (es) |
| TW (1) | TW200714282A (es) |
| UY (1) | UY29447A1 (es) |
| WO (1) | WO2006103559A1 (es) |
| ZA (1) | ZA200708033B (es) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007116265A1 (en) * | 2006-03-31 | 2007-10-18 | Pfizer Products Inc. | Process for making a tetrahydro-pyridoazepin-8-one compound |
| US8674790B2 (en) | 2009-12-28 | 2014-03-18 | Seiko Epson Corporation | Surface acoustic wave device, oscillator, module apparatus |
| US9156822B2 (en) | 2010-07-02 | 2015-10-13 | The University Of North Carolina At Chapel Hill | Functionally selective ligands of dopamine D2 receptors |
| US20140206667A1 (en) | 2012-11-14 | 2014-07-24 | Michela Gallagher | Methods and compositions for treating schizophrenia |
| MX384569B (es) | 2016-01-15 | 2025-03-14 | Pfizer | Ligandos d3 de dopamina 6,7,8,9-tetrahidro-5h-pirido[2,3-d]azepina |
| JP6974331B2 (ja) | 2016-02-05 | 2021-12-01 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 化合物、組成物及び方法 |
| RS63203B1 (sr) | 2016-12-09 | 2022-06-30 | Denali Therapeutics Inc | Jedinjenja korisna kao inhibitori ripk1 |
| US20240217977A1 (en) * | 2021-03-31 | 2024-07-04 | Blueprint Medicines Corporation | Diazepanone-fused pyrimidine compounds, compositions and medicinal applications thereof |
| IL314082A (en) | 2022-01-12 | 2024-09-01 | Denali Therapeutics Inc | Crystal forms of (S)-5-benzyl-N-(5-methyl-4-oxo-2,3,4,5-tetrahydropyrido[3,2-b][1,4]oxazapin-3-yl)- H4- 1,2,4-triazole-3-carboxamide |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2960178D1 (en) * | 1978-06-06 | 1981-04-09 | Hoechst Ag | New substituted phenylpiperazine derivatives, pharmaceutical compositions containing them and process for their preparation |
| JPS57193461A (en) * | 1981-05-22 | 1982-11-27 | Otsuka Pharmaceut Co Ltd | Benzazepine derivative |
| DK588486A (da) * | 1985-12-09 | 1987-06-10 | Otsuka Pharma Co Ltd | Anvendelse af en forbindelse til behandling af hypoxi |
| US5006528A (en) * | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
| US5350747A (en) * | 1989-07-07 | 1994-09-27 | Pfizer Inc | Heteroaryl piperazine antipsychotic agents |
| AU645681B2 (en) * | 1991-05-02 | 1994-01-20 | John Wyeth & Brother Limited | Piperazine derivatives |
| US5206366A (en) * | 1992-08-26 | 1993-04-27 | Pfizer Inc. | Process for preparing aryl piperazinyl-heterocyclic compounds |
| FR2699918B1 (fr) * | 1992-12-30 | 1995-03-17 | Pf Medicament | Ligands sélectifs des récepteurs 5HY1D-5HT1B dérivés d'indole-pipérazine utiles comme médicaments. |
| US5945422A (en) * | 1997-02-05 | 1999-08-31 | Warner-Lambert Company | N-oxides of amino containing pyrido 2,3-D! pyrimidines |
| DE19747063A1 (de) * | 1997-10-24 | 1999-04-29 | Basf Ag | 3-substituierte Tetrahydropyridopyrimidinon-Derivate, ihre Herstellung und Verwendung |
| US7160888B2 (en) * | 2003-08-22 | 2007-01-09 | Warner Lambert Company Llc | [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia |
-
2006
- 2006-03-20 CA CA002603049A patent/CA2603049A1/en not_active Abandoned
- 2006-03-20 BR BRPI0607918-0A patent/BRPI0607918A2/pt not_active Application Discontinuation
- 2006-03-20 AU AU2006228426A patent/AU2006228426A1/en not_active Abandoned
- 2006-03-20 MX MX2007012083A patent/MX2007012083A/es unknown
- 2006-03-20 AP AP2007004160A patent/AP2007004160A0/xx unknown
- 2006-03-20 EA EA200701856A patent/EA200701856A1/ru unknown
- 2006-03-20 KR KR1020077022373A patent/KR20070112228A/ko not_active Ceased
- 2006-03-20 EP EP06727493A patent/EP1869041A1/en not_active Withdrawn
- 2006-03-20 WO PCT/IB2006/000900 patent/WO2006103559A1/en not_active Ceased
- 2006-03-20 JP JP2008503619A patent/JP4109709B1/ja not_active Expired - Fee Related
- 2006-03-20 CN CNA2006800197403A patent/CN101189237A/zh active Pending
- 2006-03-28 DO DO2006000071A patent/DOP2006000071A/es unknown
- 2006-03-30 AR ARP060101253A patent/AR053835A1/es unknown
- 2006-03-30 PE PE2006000353A patent/PE20061196A1/es not_active Application Discontinuation
- 2006-03-30 UY UY29447A patent/UY29447A1/es not_active Application Discontinuation
- 2006-03-31 NL NL1031489A patent/NL1031489C2/nl not_active IP Right Cessation
- 2006-03-31 US US11/395,931 patent/US20060234997A1/en not_active Abandoned
- 2006-03-31 GT GT200600130A patent/GT200600130A/es unknown
- 2006-03-31 TW TW095111562A patent/TW200714282A/zh unknown
-
2007
- 2007-03-20 NL NL1033562A patent/NL1033562C2/nl not_active IP Right Cessation
- 2007-09-06 IL IL185770A patent/IL185770A0/en unknown
- 2007-09-18 ZA ZA200708033A patent/ZA200708033B/xx unknown
- 2007-09-28 TN TNP2007000366A patent/TNSN07366A1/fr unknown
- 2007-10-01 MA MA30264A patent/MA29989B1/fr unknown
- 2007-10-01 CR CR9407A patent/CR9407A/es not_active Application Discontinuation
- 2007-10-30 NO NO20075477A patent/NO20075477L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| MX2007012083A (es) | 2007-11-20 |
| TW200714282A (en) | 2007-04-16 |
| AR053835A1 (es) | 2007-05-23 |
| US20060234997A1 (en) | 2006-10-19 |
| NL1031489A1 (nl) | 2006-10-03 |
| MA29989B1 (fr) | 2008-12-01 |
| CN101189237A (zh) | 2008-05-28 |
| AU2006228426A1 (en) | 2006-10-05 |
| IL185770A0 (en) | 2008-01-06 |
| NO20075477L (no) | 2007-12-13 |
| WO2006103559A1 (en) | 2006-10-05 |
| DOP2006000071A (es) | 2006-10-15 |
| NL1033562C2 (nl) | 2007-10-23 |
| JP4109709B1 (ja) | 2008-07-02 |
| UY29447A1 (es) | 2006-10-31 |
| KR20070112228A (ko) | 2007-11-22 |
| JP2008534574A (ja) | 2008-08-28 |
| NL1031489C2 (nl) | 2007-04-02 |
| TNSN07366A1 (fr) | 2008-12-31 |
| EA200701856A1 (ru) | 2008-02-28 |
| BRPI0607918A2 (pt) | 2009-10-20 |
| AP2007004160A0 (en) | 2007-10-31 |
| NL1033562A1 (nl) | 2007-06-21 |
| CA2603049A1 (en) | 2006-10-05 |
| ZA200708033B (en) | 2008-11-26 |
| PE20061196A1 (es) | 2006-12-16 |
| CR9407A (es) | 2008-01-29 |
| EP1869041A1 (en) | 2007-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU23464B7 (es) | (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| UY30314A1 (es) | Derivados de benzonitrilo sustituidos con glucopiranosilo, composiciones farmacéuticas que contienen compuestos de este tipo, su uso y procedimiento para su fabricacion | |
| UY28342A1 (es) | Nuevos compuestos | |
| AR028948A1 (es) | Compuestos novedosos | |
| UY29795A1 (es) | Derivados de adenina, composiciones farmacéuticas que los contienen, procesos de preparación y aplicaciones | |
| UY29781A1 (es) | Compuestos diazaspiro sustituidos, sales farmacéuticamente aceptables, composiciones farmacéuticas que contienen los compuestos o sales, métodos de preparación y usos | |
| CR9786A (es) | Compuestos de bencimidazol-tiofeno | |
| GT200500325A (es) | Pirazolo-pirimidinas 1,4-sustituidas como inhibidores de quinasa | |
| CR8472A (es) | Indoles,1h- indazoles,1,2- benzisoxazoles y 1,2 benzisotiazoles,y preparacion y usos de los mismos | |
| UY30470A1 (es) | Compuestos heteroarilos de cinco heteroatomos sustituidos con fenilo conteniendo nitrogeno, composiciones farmacéuticas y aplicaciones. | |
| GT201000061A (es) | Derivados de uracilo o timina para el tratamiento de hepatitis c | |
| ECSP088584A (es) | Nuevos derivados de benzimidazol como inhibidores del receptor vanilloide 1 (vrl) | |
| GT200500307A (es) | Compuestos quimicos | |
| CR10304A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| GT200400146A (es) | Derivados sustituidos del dioxido de tiazol-benzoisotiazol, procedimiento para su preparacion y su uso | |
| UY29796A1 (es) | Nuevos compuestos para el tratamiento de trastornos neurológicos, psiquiátricos o del dolor | |
| DOP2006000084A (es) | Compuestos sulfoximino-macrociclicos y sus sales, composiciones farmaceuticas que comprenden dichos compuestos, metodos de preparacion y usos de los mismos | |
| UY29875A1 (es) | Compuestos quimicos | |
| UY29767A1 (es) | Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones | |
| CR9407A (es) | Tetrahidropiridoazepin-8-onas y compuestos relacionados para el tratamiento de la esquizofrenia | |
| ECSP088250A (es) | Derivados de pirazol como agentes terapéuticos | |
| UY29412A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos. | |
| GT200600161A (es) | Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos | |
| CL2009000599A1 (es) | Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras. | |
| UY27998A1 (es) | Piperazinas sustituidas sustituidas heterocíclicas para el tratamiento de la esquizofrenia |